Evaluation of Iron Bioavailability From Iron Chlorophyllin

• ClinicalTrials.gov Identifier: NCT04602247
• Recruitment Status: Completed
• First Posted: October 26, 2020
• Last Update Posted: March 26, 2021
• Sponsor: Swiss Federal Institute of Technology
• Information provided by (Responsible Party): Swiss Federal Institute of Technology

Study Description

Brief Summary:

The overall objective of this study is to evaluate the iron absorption from iron chlorophyllin. Iron deficiency is a public health problem in both developing and industrialized countries. There are several approaches to combat iron deficiency. Most supplements in the present day, to address the problem of iron deficiency, are in the form of iron salts, known as ferrous salts, especially ferrous sulfate. However, we can only usually absorb about 20% of the total iron content in ferrous sulfate. The common strategy of food supplement companies is to increase the amount of iron in the supplements to compensate for the low absorption rate. However, this often causes gastrointestinal side effects. In the present study, we would like to measure the iron bioavailability from sodium iron chlorophyllin, which made up from ferrous salts and chlorophyllin and where we hypothesize that it is absorbed via a different pathway than ferrous sulfate. Via this mechanism, we further hypothesize that sodium iron chlorophyllin will therefore have an enhanced bioavailability and more favorable side effect profile than ferrous sulfate and other iron salts.

Condition or disease	Intervention/treatment	Phase
Iron Deficiency	Dietary Supplement: SIC; Dietary Supplement: SIC + AA combined; Dietary Supplement: FeSO4; Dietary Supplement: FeSO4 + AA combined; Other: EP + FeSO4 combined; Other: EP + FeSO4 + AA combined	Not Applicable

Detailed Description:

New approaches to treat iron deficiency include developing novel iron compounds with possible iron absorption routes that increase iron bioavailability and reduce gastrointestinal side effects. Heme iron is considered to be highly bioavailable (10-20%) and less affected by meal composition than non-heme iron. Heme iron is iron (Fe2+) that is bound to the iron protoporphyrin IX prosthetic groups of proteins, mainly hemoglobin and myoglobin, which are present in animal tissue. Heme is released from hemoglobin during digestion so that it can be taken up by the duodenal enterocytes. The intact iron porphyrin is transported across the brush border membrane by the Heme Carrier Protein 1 (HCP1). Once inside the cell, the iron is released, and it is then likely to enter the low molecular weight pool of iron. The use of heme analogues from vegetable origin could provide an alternative iron source of potentially high bioavailability.

Sodium iron chlorophyllin (SIC) is a water-soluble semisynthetic chlorophyll derivative where the magnesium in the porphyrin ring has been substituted by iron. It is a greenish brown pigment that dissolves in water, alcohols, and chloroform, but not ethers. SIC is known to have a superior processing stability to chlorophyll and is commonly used as food colorings in Asian countries including in Korea and Japan, for foods that do not contain meat or fish. Magnesium Chlorophyllin has an E number of E140 and is approved as a food additive in Europe. Currently sodium iron chlorophyllin is present in the Designated Additives List in Japan with a number 261. Designated additives are those designated by the Minister of Health, Labour and Welfare as substances that are unlikely to harm human health based on Article 10 of the Food Sanitation Act.

Given the porphyrin ring heme-like structure of SIC, it may be an alternative delivery route for iron, suitable also for vegetarians and vegans, yet there are few studies investigating the use of SIC for this purpose.

A recent study by Ding et al. 2019 suggests a positive effect of SIC on hemoglobin (Hb) values in iron-deficiency anemia (IDA) in children and adults after 1 month of treatment. They assume that SIC is taken up by the heme carrier protein. The researchers used shengxuening tablets, also known as SXN, which are based on chlorophyll/porphyrin structures extracted from silkworms in which the Mg is replaced by the Fe and then coadjutants are added. This study provided no data on the absorption pathway of the SXN compound. Thus, it remains unclear if it was taken up by the heme transporter or whether it was digested and the Fe released in the gut lumen to join the non heme Fe pool, and thereby improved Hb in the IDA subjects. The authors also describe Xray diffraction assays to assess if the chlorophyllin porphyrin ring contained Fe and not Mg, however these data are not reported.

Miret et al. (2010) studied the stability of heme-analogous SIC absorption using the Caco-2 cell model. The SIC remained stable and only 5% of the Fe from the compound was released at pH 2 to 4. In-house dissolution studies conducted at the Human Nutrition Laboratory (HNL) show only a 2% release of Fe from the compound at similar pH levels. Using solid phase extraction at a higher pH of 7, similar to that in the duodenum, we observed a 5% Fe loss, which may correspond to free iron or iron liberated from any other binding sites on the chlorophyll structure.

Toyoda et al. (2014) performed a toxicity study of SIC performed in male and female rats with oral administration of SIC in their diet at concentrations of 0%, 0.2%, 1.0%, and 5.0% for 13 weeks. No abnormal clinical signs, no mortality and no abnormal hematological changes were observed in any of the groups during the experiment. Based on the histopathology of the parotid glands, the no-observed-adverse-effect level (NOAEL) of SIC in this study was estimated to be 1.0% (609 mg SIC/kg bodyweight (bw)/day for males and 678 mg/kg bw/day for females). In the present study, we will use 6 mg elemental iron, in 100 mg SIC, 0.002% of the equivalent dose administered by Toyoda et al.

SIC has been produced at the HNL with a 75% incorporation of iron into the chlorophyll. Our protocol is based on a Unilever patent that is no longer active, with in-house adaptation. The SIC has a neutral taste and will be presented as a dark green liquid, being the solution of SIC in water.

The goal of this project is to develop a novel iron compound that can be used as a food supplement. The iron content in our SIC will be limited to 6 mg per dose, which therefore does not exceed the 14 mg daily iron dose stipulated as the legal maximum in Switzerland for food supplements. SIC is already used widely as a food colorant and is safe for human consumption.

We propose to test our SIC against a known comparator, ferrous sulfate, to ascertain whether SIC is an effective iron delivery compound. If SIC, as hypothesized, behaves in a similar way to heme, then commonly used enhancers of iron absorption effective on ferrous sulfate, such as ascorbic acid, will not have an effect on the absorption of iron from SIC

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 55 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment

Intervention Model Description

The study will be a single-center, prospective cross-over trial in which each subject receives all test conditions. During the screening, about 2 weeks before the start of the study, women will be assessed for eligibility. Finally, 55 eligible women will be invited to participate.

Each subject will complete six iron absorption studies in which they will receive supplemental iron doses of 6 mg iron.The experimental phase will last for 37 days. The labeled iron doses will be administered on days 1, 3, 5, 19, 21 and 23. Since only three isotopes are used in the study, after day 5, there will be a wait period of 14 days to allow for incorporation of the labeled iron into erythrocytes. On day 19, 21 and 23 the other three test doses are administered. Randomization of the interventional products listed above will be set up as such, to ensure that participants do not receive the same isotopes in a given week. On day 1, day 19 and day 37, a venous blood sample will be collected.

• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Evaluation of Iron Bioavailability From Iron Chlorophyllin in Young Women Using the Iron Stable Isotopic Method
• Actual Study Start Date: October 26, 2020
• Actual Primary Completion Date: December 14, 2020
• Actual Study Completion Date: December 14, 2020

Arms and Interventions

Arm	Intervention/treatment
Experimental: SIC; 100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe.	Dietary Supplement: SIC; Sodium Iron Chlorophyllin, whose bioavailability is to be studied
Experimental: SIC + AA combined; 100 mg sodium iron chlorophyllin (SIC) containing 6 mg 57 Fe given with 40 mg Ascorbic Acid	Dietary Supplement: SIC + AA combined; Sodium Iron Chlorophyllin and ascorbic acid. The ascorbic acid should not have an effect on Sodium Iron Chlorophyllin
Active Comparator: FeSO4; 6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe	Dietary Supplement: FeSO4; Ferrous sulfate serves as a positive control, whose iron bioavailability is known
Active Comparator: FeSO4 + AA combined; 6mg of FeSO4 given as 4 mg 56Fe and 2mg 58Fe along with 40 mg Ascorbic Acid	Dietary Supplement: FeSO4 + AA combined; Ferrous sulfate serves as a positive control and the addition of ascorbic acid, further enhances its bioavailability
Experimental: EP + FeSO4 combined; 100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe	Other: EP + FeSO4 combined; Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system
Experimental: EP + FeSO4 + AA combined; 100 mg of Chlorophyllin without the Magnesium central atom along with 6 mg FeSO4 as 54 Fe along with 40 mg of Ascorbic Acid	Other: EP + FeSO4 + AA combined; Chlorophyllin with an empty porphyrin ring, given along with FeSO4 to study if there is an incorporation of Fe into the porphyrin ring as it passes the gastric system. Ascorbic acid is given along with the intervention to see if there is any difference in the fractional iron absorption when compared to EP+ FeSO4

Outcome Measures

Primary Outcome Measures :

1. Fractional Iron Absorption [ Time Frame: day 19 ]
   Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the intervention products .Fractional iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements.
2. Fractional Iron Absorption [ Time Frame: day 37 ]
   Fractional iron absorption will be calculated based on the shift of the iron isotope ratios in the collected blood samples after the administration of the intervention products .Fractional iron absorption will be measured as erythrocyte incorporation of the naturally occurring iron forms with different masses used to label the iron supplements.

Secondary Outcome Measures :

1. Hemoglobin [ Time Frame: Day 1, day 19 and day 37 of the study ]
   Iron status marker
2. Plasma Ferritin [ Time Frame: Day 1, day 19 and day 37 of the study ]
   Iron status marker
3. soluble transferrin receptor (sTfR) [ Time Frame: Day 1, day 19 and day 37 of the study ]
   Iron status marker
4. C-Reactive Protein [ Time Frame: Day 1, day 19 and day 37 of the study ]
   Inflammation marker

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 40 Years (Adult)
• Sexes Eligible for Study: Female
• Gender Based Eligibility: Yes
• Gender Eligibility Description: Female
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• female aged between 18-45 y old;
• SF <80 µg/L;
• BMI 18.5-24.9 kg/m2;
• weight <70 kg;
• signed informed consent;
• able to communicate and comprehend English language

Exclusion Criteria:

• anemia (Hb <12 g/dL);
• inflammation (CRP > 5 mg/L);
• chronic digestive, renal and/or metabolic disease;
• chronic medications (except for oral contraceptives);
• use of vitamin, mineral and pre- and/or probiotic supplements in the previous 2 weeks before study initiation and during the course of the study;
• blood transfusion, blood donation or significant blood loss over the past 4 months;
• pregnancy (tested in serum at screening) or intention to become pregnant;
• lactation up to 6 weeks before study initiation;
• earlier participation in a study using stable isotopes or participation in any clinical study within the last 30 days;
• smoking;
• unwilling to use an effective method of contraception.

Contacts and Locations

Locations

Switzerland

ETH Zürich, Laboratory of Human Nutrition

Zürich, ZH, Switzerland, 8092

Sponsors and Collaborators

Swiss Federal Institute of Technology

More Information

• Responsible Party: Swiss Federal Institute of Technology
• ClinicalTrials.gov Identifier: NCT04602247
• Other Study ID Numbers: SIC2020
• First Posted: October 26, 2020
• Last Update Posted: March 26, 2021
• Last Verified: March 2021

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Swiss Federal Institute of Technology:

iron deficiency; Iron chlorophyllin

Additional relevant MeSH terms:

Anemia, Iron-Deficiency; Anemia, Hypochromic; Anemia; Hematologic Diseases; Iron Metabolism Disorders; Metabolic Diseases; Fesoterodine; Muscarinic Antagonists; Cholinergic Antagonists; Cholinergic Agents; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Physiological Effects of Drugs; Urological Agents